$3SBIO(01530)$ just landed a p

$3SBIO(01530)$ just landed a pretty sweet deal with $Pfizer(PFE)$ ，all overseas development and commercialization are handled by Pfizer, while 3SBio keeps the China rights. That means nearly all the revenue from this deal drops straight to the bottom line, with minimal cost burden.

Pfizer’s decision to go with SSGJ-707 isn’t just about product potential. What really sealed the deal was 3SBio’s clear partnership structure and willingness to cede global control. Pfizer gets exclusive rights worldwide (except China) and plans to build its own manufacturing facilities in North Carolina and Kansas, ensuring full value-chain dominance.

And let’s not forget the $100M equity investment，that’s a serious commitment to long-term alignment.

Winning Trades

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":440565050224816,"tweetId":"440565050224816","gmtCreate":1748586619975,"gmtModify":1748592168243,"author":{"id":10000000000010956,"idStr":"10000000000010955","authorId":10000000000010956,"authorIdStr":"10000000000010955","name":"Porter Harry","avatar":"https://static.tigerbbs.com/6b5dd5252a1bca34909f191e8c9ba404","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/45b44313fbb5a2b89c5da0356c311b0b","width":"767","height":"1280"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/45b44313fbb5a2b89c5da0356c311b0b","width":"767","height":"1280"}],"html":"<html><head></head><body> <a data-mention-id=\"01530\" class=\"teditor-mention\" data-mention-name=\"3SBIO\" href=\"https://ttm.financial/S/01530\">$3SBIO(01530)$</a> just landed a pretty sweet deal with <a data-mention-id=\"PFE\" class=\"teditor-mention\" data-mention-name=\"Pfizer\" href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a> ，all overseas development and commercialization are handled by Pfizer, while 3SBio keeps the China rights. That means nearly all the revenue from this deal drops straight to the bottom line, with minimal cost burden. Pfizer’s decision to go with SSGJ-707 isn’t just about product potential. What really sealed the deal was 3SBio’s clear partnership structure and willingness to cede global control. Pfizer gets exclusive rights worldwide (except China) and plans to build its own manufacturing facilities in North Carolina and Kansas, ensuring full value-chain dominance. And let’s not forget the $100M equity investment，that’s a serious commitment to long-term alignment.<img src=\"https://community-static.tradeup.com/news/45b44313fbb5a2b89c5da0356c311b0b\" tg-width=\"767\" tg-height=\"1280\"></body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"01530\" class=\"teditor-mention\" data-mention-name=\"3SBIO\" href=\"https://ttm.financial/S/01530\">$3SBIO(01530)$</a> just landed a pretty sweet deal with <a data-mention-id=\"PFE\" class=\"teditor-mention\" data-mention-name=\"Pfizer\" href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a> ，all overseas development and commercialization are handled by Pfizer, while 3SBio keeps the China rights. That means nearly all the revenue from this deal drops straight to the bottom line, with minimal cost burden. Pfizer’s decision to go with SSGJ-707 isn’t just about product potential. What really sealed the deal was 3SBio’s clear partnership structure and willingness to cede global control. Pfizer gets exclusive rights worldwide (except China) and plans to build its own manufacturing facilities in North Carolina and Kansas, ensuring full value-chain dominance. And let’s not forget the $100M equity investment，that’s a serious commitment to long-term alignment.<img src=\"https://community-static.tradeup.com/news/45b44313fbb5a2b89c5da0356c311b0b\" tg-width=\"767\" tg-height=\"1280\"></body></html>","text":"$3SBIO(01530)$ just landed a pretty sweet deal with $Pfizer(PFE)$ ，all overseas development and commercialization are handled by Pfizer, while 3SBio keeps the China rights. That means nearly all the revenue from this deal drops straight to the bottom line, with minimal cost burden. Pfizer’s decision to go with SSGJ-707 isn’t just about product potential. What really sealed the deal was 3SBio’s clear partnership structure and willingness to cede global control. Pfizer gets exclusive rights worldwide (except China) and plans to build its own manufacturing facilities in North Carolina and Kansas, ensuring full value-chain dominance. And let’s not forget the $100M equity investment，that’s a serious commitment to long-term alignment.","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/440565050224816","repostId":0,"isVote":1,"tweetType":1,"viewCount":1802,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["01530","PFE"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":true,"length":631,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/440565050224816"}